What happened to Sava stock after it risen 1000% last year?
SAVA stock ran up more than 1,000% at one point last year on hopes of an imminent breakthrough in the treatment of Alzheimer’s. However, that euphoria has given way in 2022.
What is Sernova's (SVA) stock worth?
Since then, SVA stock has increased by 906.9% and is now trading at C$1.46. View which stocks have been most impacted by COVID-19. When is Sernova's next earnings date? Sernova is scheduled to release its next quarterly earnings announcement on Monday, February 7th 2022. View our earnings forecast for Sernova.
How much is a share of SVA biotech worth?
One share of SVA stock can currently be purchased for approximately $6.47. How much money does Sinovac Biotech make? Sinovac Biotech has a market capitalization of $642.41 million and generates $510.62 million in revenue each year.
How do I buy shares of SVA?
Shares of SVA and other Canadian stocks can be purchased through an online brokerage account.
When will Sinovac Biotech release its earnings?
What is the P/E ratio of Sinovac Biotech?
What is Sinovac Biotech?
Is there enough data for Sinovac Biotech?
Does Sinovac pay dividends?
When is Sinovac Biotech's next earnings date?
Sinovac Biotech is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022. View our earnings forecast for Sinovac...
Who are Sinovac Biotech's key executives?
Sinovac Biotech's management team includes the following people: Dr. Weidong Yin , Chairman, CEO, Pres, MD, GM & Sec. (Age 56) Ms. Nan Wang , C...
Who are some of Sinovac Biotech's key competitors?
Some companies that are related to Sinovac Biotech include Pacira BioSciences (PCRX) , AbCellera Biologics (ABCL) , Amicus Therapeutics (FOLD) ,...
What other stocks do shareholders of Sinovac Biotech own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sinovac Biotech investors own include Pfizer (PFE) , Gile...
What is Sinovac Biotech's stock symbol?
Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."
Who are Sinovac Biotech's major shareholders?
Sinovac Biotech's stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group S...
What is Sinovac Biotech's stock price today?
One share of SVA stock can currently be purchased for approximately $6.47.
How much money does Sinovac Biotech make?
Sinovac Biotech (NASDAQ:SVA) has a market capitalization of $643.77 million and generates $19.37 billion in revenue each year.
How many employees does Sinovac Biotech have?
Sinovac Biotech employs 4,281 workers across the globe.
Is SVA stock a buy right now?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sernova in the last twelve months. There are currently 1...
How has Sernova's stock performed in 2022?
Sernova's stock was trading at C$1.82 at the start of the year. Since then, SVA stock has decreased by 13.7% and is now trading at C$1.57. View th...
When is Sernova's next earnings date?
Sernova is scheduled to release its next quarterly earnings announcement on Friday, June 24th 2022. View our earnings forecast for Sernova .
How were Sernova's earnings last quarter?
Sernova Corp. (CVE:SVA) announced its quarterly earnings results on Tuesday, March, 29th. The company reported ($0.02) earnings per share (EPS) for...
Who are some of Sernova's key competitors?
Some companies that are related to Sernova include MaxCyte (MXCT) , Profound Medical (PRN) , Renalytix (RENX) , Profound Medical (PRN) , Akumi...
What other stocks do shareholders of Sernova own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sernova investors own include Gilead Sciences (GILD) , Ne...
What is Sernova's stock symbol?
Sernova trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SVA."
How do I buy shares of Sernova?
Shares of SVA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian...
What is Sernova's stock price today?
One share of SVA stock can currently be purchased for approximately C$1.57.
Who is SVA in 2021?
BEIJING, June 30, 2021--Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced The Lancet Infectious Diseases published results from the Phase I/II clinical trials of an inactivated COVID-19 vaccine developed by SINOVAC, also known as CoronaVac®, in healthy children and adolescents aged 3-17 in China.
Is Sinovac available in Singapore?
Offering Sinovac Biotech COVID-19 vaccines to the public in Singapore for the first time since Friday, several private clinics reported overwhelming demand for the Chinese-made shot, despite already available rival vaccines having far higher efficacy. Singapore has vaccinated almost half its 5.7 million population with at least one dose of the vaccines from Pfizer-BioNTech and Moderna. Both have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with Sinovac's 51%.
What is the SVA symbol?
Sernova trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SVA."
What is a Sernova cell pouch?
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
What is the official website of Sernova?
The official website for Sernova is www.sernova.com.
What is the P/E ratio of Sernova?
The P/E ratio of Sernova is -48.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Sernova pay dividends?
Sernova does not currently pay a dividend.
What is Sinovac Biotech?
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company’s product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Where is Sinovac Biotech located?
Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Who approved the second Sinovac shot?
WHO approves Sinovac COVID shot in second Chinese milestone: The World Health Organization (WHO) said on Tuesday it has approved a COVID-19 vaccine made by Sinovac Biotech (SVA.O) for emergency use listing, paving the way for a second Chinese shot to be used in poor countries.
How old do you have to be to get a Sinovac shot?
The WHO's independent panel of experts said in a statement it recommended Sinovac's vaccine for adults over 18. There was no upper age limit as data suggested it is likely to have a protective effect in older people. ...
Why is cassava stock so high in 2021?
Cassava's stock has skyrocketed because the company has a new approach to Alzheimer's treatment.
Did the SEC investigate Cassava?
The report comes just two days after Cassava, in an SEC filing, revealed that “certain government agencies” had asked the Company for documentation. It wasn’t clear which agencies were inquiring or what information they sought , and Cassava did say that the requests weren’t accusations of wrongdoin
Is Cassava Sciences a stock?
Cassava Sciences, one of best-performing U.S. stocks this year, has denied claims that it manipulated research results.
What is Sinovac Biotech?
Sinovac Biotech Ltd is a biopharmaceutical company. The company primarily focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases.
Does market cap include convertible securities?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Short Interest ()
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.
Per-Share Earnings, Actuals and Estimates
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet.
When will Sinovac Biotech release its earnings?
Sinovac Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 27th 2021. View our earnings forecast for Sinovac Biotech.
What is the P/E ratio of Sinovac Biotech?
The P/E ratio of Sinovac Biotech is 6.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.90.
What is Sinovac Biotech?
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Is there enough data for Sinovac Biotech?
There is not enough analysis data for Sinovac Biotech.
Does Sinovac pay dividends?
Sinovac Biotech does not currently pay a dividend.
